- Organizations: Cloudbreak Pharma
Pipeline
Cloudbreak Pharma releases positive phase 3 topline data on pterygium therapy
Data demonstrate durable reductions in pterygium vascularity with a favorable safety profile; company intends to review findings with FDA.Pipeline
FDA clears Cloudbreak Pharma's IND for phase 2 presbyopia drop trials
Clearance green lights advancement of CBT-199, an ophthalmic emulsion with a proprietary, water-free formulation and parasympathomimetic miotic agent.Pipeline